Cambium Bio (Australia) Performance
| CMB Stock | 0.51 0.01 2.00% |
On a scale of 0 to 100, Cambium Bio holds a performance score of 13. The firm shows a Beta (market volatility) of -0.0227, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cambium Bio are expected to decrease at a much lower rate. During the bear market, Cambium Bio is likely to outperform the market. Please check Cambium Bio's coefficient of variation, jensen alpha, sortino ratio, as well as the relationship between the information ratio and total risk alpha , to make a quick decision on whether Cambium Bio's price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cambium Bio are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental drivers, Cambium Bio unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:100 | Last Split Date 2024-07-04 |
1 | Can machine learning forecast BAC.PRS recovery - Options Play Fast Gain Stock Trading Tips - Newser | 08/22/2025 |
2 | Exit strategy if youre trapped in Tevogen Bio Holdings Inc. Equity Warrant - Earnings Miss Real-Time Volume Analysis Alerts - Newser | 08/27/2025 |
3 | Locus Cells Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio - PR Newswire | 09/29/2025 |
| Begin Period Cash Flow | 2.9 M |
Cambium |
Cambium Bio Relative Risk vs. Return Landscape
If you would invest 37.00 in Cambium Bio on August 14, 2025 and sell it today you would earn a total of 14.00 from holding Cambium Bio or generate 37.84% return on investment over 90 days. Cambium Bio is generating 0.5501% of daily returns assuming 3.1838% volatility of returns over the 90 days investment horizon. Simply put, 28% of all stocks have less volatile historical return distribution than Cambium Bio, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cambium Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cambium Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cambium Bio, and traders can use it to determine the average amount a Cambium Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1728
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CMB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.18 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.55 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Cambium Bio is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cambium Bio by adding it to a well-diversified portfolio.
Cambium Bio Fundamentals Growth
Cambium Stock prices reflect investors' perceptions of the future prospects and financial health of Cambium Bio, and Cambium Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cambium Stock performance.
| Return On Equity | -3.55 | ||||
| Return On Asset | -0.63 | ||||
| Current Valuation | 11.92 M | ||||
| Shares Outstanding | 22.97 M | ||||
| Price To Book | 6.32 X | ||||
| Price To Sales | 1,914 X | ||||
| Revenue | 988.43 K | ||||
| Gross Profit | 1.02 M | ||||
| EBITDA | (724.6 K) | ||||
| Net Income | (3.84 M) | ||||
| Total Debt | 317 K | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (660.46 K) | ||||
| Earnings Per Share | (0.21) X | ||||
| Total Asset | 3.3 M | ||||
| Retained Earnings | (46.59 M) | ||||
About Cambium Bio Performance
Assessing Cambium Bio's fundamental ratios provides investors with valuable insights into Cambium Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cambium Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cambium Bio is entity of Australia. It is traded as Stock on AU exchange.Things to note about Cambium Bio performance evaluation
Checking the ongoing alerts about Cambium Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cambium Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cambium Bio has some characteristics of a very speculative penny stock | |
| Cambium Bio appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 988.43 K. Net Loss for the year was (3.84 M) with profit before overhead, payroll, taxes, and interest of 1.02 M. | |
| Cambium Bio generates negative cash flow from operations | |
| About 63.0% of the company shares are held by company insiders |
- Analyzing Cambium Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cambium Bio's stock is overvalued or undervalued compared to its peers.
- Examining Cambium Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cambium Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cambium Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cambium Bio's stock. These opinions can provide insight into Cambium Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cambium Stock Analysis
When running Cambium Bio's price analysis, check to measure Cambium Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cambium Bio is operating at the current time. Most of Cambium Bio's value examination focuses on studying past and present price action to predict the probability of Cambium Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cambium Bio's price. Additionally, you may evaluate how the addition of Cambium Bio to your portfolios can decrease your overall portfolio volatility.